(Q62944906)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23467812%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

title

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23467812%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23467812%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Vicente Alfaro

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23467812%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Luca Gianni

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23467812%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

author name string

Cristiana Sessa

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23467812%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Gianluca Del Conte

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23467812%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Alexandre Christinat

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23467812%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Antonella Perotti

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23467812%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Elisa Gallerani

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23467812%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Pilar Lardelli

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23467812%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Carmen Kahatt

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23467812%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Carlos Fernández-Teruel

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23467812%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Jorge L Iglesias

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23467812%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

publication date

7 March 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23467812%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

25 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23467812%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23467812%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23467812%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

page(s)

1236-1243

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23467812%20AND%20SRC:MED&resulttype=core&format=json

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

25 February 2020

cites work

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry

1 reference

12 December 2020

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

1 reference

12 December 2020

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens

1 reference

12 December 2020

Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone

1 reference

12 December 2020

A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials

1 reference

12 December 2020

Role of homologous recombination in trabectedin-induced DNA damage

1 reference

12 December 2020

Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.

1 reference

12 December 2020

Population pharmacokinetics of total and unbound plasma cisplatin in adult patients

1 reference

12 December 2020

Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors

1 reference

12 December 2020

DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata

1 reference

12 December 2020

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

1 reference

12 December 2020

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.

1 reference

12 December 2020

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

1 reference

12 December 2020

Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients

1 reference

12 December 2020

Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients.

1 reference

12 December 2020

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

1 reference

12 December 2020

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

1 reference

12 December 2020

Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study

1 reference

12 December 2020

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

12 December 2020

The combination of yondelis and cisplatin is synergistic against human tumor xenografts

1 reference

12 December 2020

Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate

1 reference

12 December 2020

A review of trabectedin (ET-743): a unique mechanism of action.

1 reference

12 December 2020

Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways

1 reference

12 December 2020

Interaction of anticancer drug cisplatin with guanine: Density functional theory and surface‐enhanced Raman spectroscopy study

1 reference

12 December 2020

A phase III randomized study comparing paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with advanced ovarian cancer

1 reference

12 December 2020

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

1 reference

12 December 2020

Simple and sensitive liquid chromatographic quantitative analysis of the novel marine anticancer drug Yondelis (ET-743, trabectedin) in human plasma using column switching and tandem mass spectrometric detection

1 reference

12 December 2020

Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove

1 reference

12 December 2020